Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05884398 · ClinicalTrials.gov registry record · Phase 3
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
A Phase 3 study of Metastatic Castrate-sensitive Prostate Cancer, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 420
- Enrollment target
- 20
- Study locations
NCT05884398 is a Phase 3 study of Metastatic Castrate-sensitive Prostate Cancer that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 420 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT05884398, a Phase 3 study of Metastatic Castrate-sensitive Prostate Cancer, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 420 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate-specific antigen (PSA) level \< 0.2 nanograms/millilitres (ng/mL) after 6 months of treatment with apalutamide and ADT combination therapy provides non-inferior radiographic progression-free survival (rPFS) and a reduced burden of hot flashes measured as 18-month percent change in severity adjusted hot flash score.
Conditions Studied
Interventions
- DRUG Apalutamide
- DRUG Androgen-deprivation Therapy (ADT)
Study Locations (20)
California
- Urology Associates of Central California - Fresno
- VA Medical Center - San Francisco
- Sansum Clinic Pharm - Santa Barbara
New Jersey
- MSKCC Basking Ridge - Basking Ridge
- MSKCC Monmouth - Middletown
- MSKCC Bergen - Montvale
Arizona
- Del Sol Research Management, LLC - Tucson
- Arizona Urology Specialists - Tucson
Illinois
- Associated Urological Specialists LLC - Chicago Ridge
- Advanced Urology Associates - Joliet
Indiana
- Urology of Indiana - Greenwood
- First Urology, PSC - Jeffersonville
Maryland
- Maryland Oncology Hematology P A - Silver Spring
- Chesapeake Urology Research Associates - Towson
Alabama
- Urology Centers Of Alabama - Homewood
Arkansas
- Arkansas Urology - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2023-08-31 |
| Est. Completion | 2028-10-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05884398
The ClinicalTrials.gov registry entry for NCT05884398 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Castrate-sensitive Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Apalutamide is the first listed.
NCT05884398 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, New Jersey, Arizona.
Frequently Asked Questions
What is clinical trial NCT05884398 about?
NCT05884398 is a clinical study titled "A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC". The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate-specific antigen (PSA) level \< 0.2 nanograms/millilitres (ng/mL) after 6 months of treatment with ...
What is the current status of trial NCT05884398?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 420 participants. The study started on 2023-08-31. Estimated completion is 2028-10-12.
What conditions does trial NCT05884398 study?
This clinical trial studies the following conditions: Metastatic Castrate-sensitive Prostate Cancer.
What interventions are being tested in trial NCT05884398?
The interventions under investigation include: Apalutamide (DRUG), Androgen-deprivation Therapy (ADT) (DRUG).
Who is sponsoring clinical trial NCT05884398?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05884398 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.